Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | unspecified product | 0.004 | 0.0108 | 0.0146 |
Loa Loa (eye worm) | hypothetical protein | 0.1672 | 1 | 1 |
Toxoplasma gondii | hypothetical protein | 0.1672 | 1 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.0793 | 0.4669 | 1 |
Giardia lamblia | MRP-like ABC transporter | 0.0029 | 0.0041 | 1 |
Giardia lamblia | Multidrug resistance-associated protein 1 | 0.0029 | 0.0041 | 1 |
Trypanosoma brucei | ingi protein (ORF1) | 0.004 | 0.0108 | 0.0146 |
Echinococcus multilocularis | multidrug resistance associated protein 1 | 0.0029 | 0.0041 | 1 |
Leishmania major | ATP-binding cassette protein subfamily C, member 2, putative | 0.0029 | 0.0041 | 0.5 |
Brugia malayi | multidrug resistance related protein 1 | 0.0029 | 0.0041 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0029 | 0.0041 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0793 | 0.4669 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.004 | 0.0108 | 0.0146 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0041 | 0.5 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0041 | 0.5 |
Loa Loa (eye worm) | ABC transporter transmembrane region family protein | 0.0029 | 0.0041 | 0.0039 |
Leishmania major | ABC-thiol transporter | 0.0029 | 0.0041 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1672 | 1 | 1 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0041 | 0.5 |
Echinococcus granulosus | multidrug resistance associated protein 7 | 0.0029 | 0.0041 | 1 |
Loa Loa (eye worm) | inward rectifying k channel family protein 1 | 0.1672 | 1 | 1 |
Trypanosoma cruzi | multidrug resistance-associated protein, putative | 0.0029 | 0.0041 | 1 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0041 | 0.5 |
Leishmania major | ATP-binding cassette protein subfamily C, member 1, putative | 0.0029 | 0.0041 | 0.5 |
Entamoeba histolytica | ABC transporter, putative | 0.0029 | 0.0041 | 0.5 |
Echinococcus multilocularis | multidrug resistance associated protein 7 | 0.0029 | 0.0041 | 1 |
Leishmania major | p-glycoprotein e | 0.0029 | 0.0041 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.0041 | 0.0039 |
Echinococcus granulosus | multidrug resistance associated protein 1 | 0.0029 | 0.0041 | 1 |
Leishmania major | ATP-binding cassette protein subfamily C, member 6, putative | 0.0029 | 0.0041 | 0.5 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.004 | 0.0108 | 0.0146 |
Leishmania major | ATP-binding cassette protein subfamily C, member 5, putative | 0.0029 | 0.0041 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.0039 | 0.0038 |
Trypanosoma cruzi | multidrug resistance protein E, putative | 0.0029 | 0.0041 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.0041 | 0.0039 |
Trypanosoma cruzi | multidrug resistance-associated protein, putative | 0.0029 | 0.0041 | 1 |
Trypanosoma brucei | ingi protein (ORF1) | 0.004 | 0.0108 | 0.0146 |
Giardia lamblia | ABC transporter, putative | 0.0029 | 0.0041 | 1 |
Leishmania major | pentamidine resistance protein 1 | 0.0029 | 0.0041 | 0.5 |
Brugia malayi | ABC transporter transmembrane region family protein | 0.0029 | 0.0041 | 0.5 |
Giardia lamblia | Multidrug resistance-associated protein 1 | 0.0029 | 0.0041 | 1 |
Entamoeba histolytica | multidrug resistance protein, putative | 0.0029 | 0.0041 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 5.5 % | Induction of apoptosis in human M21 cells at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 5.5 % | Induction of apoptosis in human M21 cells at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 9.9 % | Induction of apoptosis in human M21 cells at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 9.9 % | Induction of apoptosis in human M21 cells at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 11.9 % | Induction of apoptosis in human M21 cells at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 11.9 % | Induction of apoptosis in human M21 cells at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 12.4 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 12.4 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 12.9 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 12.9 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 15.6 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 15.6 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 19.5 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 19.5 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 21 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 21 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 21.9 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 21.9 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 37.4 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 37.4 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 38.1 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 38.1 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 38.8 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 38.8 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
GI50 (functional) | = 1.18 uM | Growth inhibition of human HT29 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 1.18 uM | Growth inhibition of human HT29 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 8.38 uM | Growth inhibition of human M21 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 8.38 uM | Growth inhibition of human M21 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 14 uM | Growth inhibition of human MCF7 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 14 uM | Growth inhibition of human MCF7 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 17.4 uM | Growth inhibition of human MDA-MB-231 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 17.4 uM | Growth inhibition of human MDA-MB-231 cells | ChEMBL. | 17291753 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.